The week in health tech, explained in plain English.Get the free newsletter →
October 9, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

KFF Reporters Track Opioid Settlement Cash and Raw-Milk Risks

By Healthcare Technology News ·

KFF Health News reporters fanned out across national and local media to unpack several public health stories, with the most consequential being how states and counties are spending the more than $50 billion flowing from opioid settlements, according to KFF Health News. The reporting continues to probe whether that money reaches addiction treatment and prevention or gets diverted to unrelated budget holes, a question that has dogged the payouts since they began.

The journalists also addressed the marketing of raw milk and a related infant formula recall, warning that unpasteurized products carry infection risks that marketing claims tend to downplay. A separate segment examined the mounting health dangers of extreme heat, which strains emergency departments and hits vulnerable patients hardest.

Each thread points to the same underlying issue. Large sums of public money and high-stakes health choices frequently move with limited transparency, and independent reporting remains one of the few checks tracking where the dollars land and who gets hurt.

Sources

More in Government

Government

White House Plans $100M STEM PhD Push as NIH Sheds Scientists

The Trump administration plans to put over $100 million into STEM PhD fellowships, announced at an Oct. 8 White House summit, even as the NIH loses scientists.

Why it matters: The PhD pipeline fuels biomedical research across hospitals and biotech, but new fellowship funding may not offset talent losses at the NIH.

Government

Stem Cell Advocates Eye FDA Opening Under RFK Jr.

Stem cell advocates hope the FDA will grant their unproven therapies legitimacy under RFK Jr., mirroring how peptides gained acceptance through the MAHA movement.

Why it matters: If regulatory politics rather than clinical evidence starts shaping FDA acceptance, it could reshape patient access and safety standards across emerging therapies.

Government

Ashish Jha Warns AI Is Lowering the Bar for Bioweapons

Ashish Jha warns in STAT News that AI is eroding the barriers that kept biological weapons rare, and defenses will take years the world cannot spare.

Why it matters: If AI makes bioweapons easier to build faster than defenses can be developed, the risk to public health and national security grows sharply.